Patricio O’Donnell, MD, PhD is Vicepresident and Head of Translational Medicine at Alto Neuroscience. Dr. O’Donnell grew up in Buenos Aires, Argentina and earned his M.D. and Ph.D. degrees from the University of Buenos Aires. Dr. O’Donnell worked as a postdoctoral fellow with Anthony Grace at the University of Pittsburgh, where he pioneered studies on the physiological properties of the nucleus accumbens, and then moved on to establishing his own research program at Albany Medical College. In 2006 he was recruited by the University of Maryland, where he led a successful and well-funded lab exploring brain physiology aspects in animal models of neuropsychiatric conditions. In 2013 he transitioned to industri, joining Pfizer as Head of Psychiatry Research. In 2017 he joined Takeda Translational Research and Early Clinic group, and in 2022 he moved to lead translational medicine efforts at Sage Therapeutics. In June 2024, he moved to his current position at Alto Neuroscience, where he is contributing to the personalized psychiatry emphasis of this exciting company. Patricio is the recipient of numerous awards including the 2010 National Alliance for Schizophrenia and Depression Distinguished Investigator Award. Dr. O’Donnell is a fellow in the American College of Neuropsychopharmacology (ACNP), chaired several conferences including the 2009 Gordon Conference on Catecholamines and the Winter Conference on Brain Research in 2012 and 2013. Dr. O’Donnell has authored over 120 scientific papers, served or serves on the Editorial Boards of the Journal of Neuroscience, Neuropsychopharmacology, The International Journal of Neuropsychopharmacology, Schizophrenia Bulletin, and the Journal of Pharmacology & Experimental Therapeutics, among others, and sat on advisory committees of the National Institutes of Health. He serves on the scientific advisory board of several private foundations and has advised major pharmaceutical and biotech companies.